SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Pastimesvitamins herbs supplements longevity and aging


Previous 10 Next 10 
To: Yorikke who wrote (16170)6/22/2022 2:02:21 PM
From: Pogeu Mahone
   of 16226
 
Try reading. It works no matter what you believe.
Enjoy the day.

Share RecommendKeepReplyMark as Last Read


From: Pogeu Mahone6/23/2022 7:15:35 AM
   of 16226
 
New omicron variants target lungs and escape antibodies


Preliminary research from the University of Tokyo has sparked a debate about whether the newest omicron variants are of great concern or not

By Gitanjali Poonia gpoonia@deseretnews.com
Jun 22, 2022, 11:37am EDT

Omicron variants are driving new infections across the world, proving to evade antibodies.

Why it matters: Preliminary research from the University of Tokyo suggests that the alpha and delta strains produced more severe illnesses compared to omicron, which creates cold or allergy-like symptoms, per The Independent.

But this research reveals something more important — the new omicron variants have evolved to target lung cells again, drawing similarities to its origin strains.

US rolls out COVID-19 vaccines for youngest kids
The nation’s youngest children are getting their chance at COVID-19 vaccines as the U.S. rolls out shots this week. Parents of infants and preschoolers lined up Tuesday for tot-sized doses of Pfizer's vaccine at Children's National Hospital in Washington. (AP video/Angie Wang) - Source: ASSOCIATED PRESS

New omicron subvariants BA.4 BA.5 are worrying experts New omicron variants account for 21% of all cases in U.S.
What they’re saying: The risk that strains BA.4 and BA.5 pose “to global health is potentially greater than that of original BA.2,” said Dr. Kei Sato, the study’s lead author
, per The Guardian.

“It looks as though these things are switching back to the more dangerous form of infection, so going lower down in the lung,” said Dr. Stephen Griffin, a virologist at the University of Leeds, per the report.

By the numbers: Earlier in June, the BA.4 and BA.5 only constituted 6% and 7% of all cases in the U.S., respectively. Three weeks later, the BA.5 strain alone makes up 23.5% of cases in the U.S., while BA.4 has a hold on 11.4%, according to the Centers for Disease Control and Prevention tracker.

RELATED
You shouldn’t always trust a negative COVID test, doctors say

Omicron variants BA.4 and BA. 5 cause surge in deaths and cases in Portugal

Do vaccines work?: Industry experts in Japan, scientists in South Africa and researchers at Columbia University all concluded that the vaccines and prior infections offer less protection against the newest strains, BA.4 and BA.5, compared to older omicron strains like BA.1 and BA.2, wrote Betsy Ladyshets for Time magazine.

Worth noting: South Africa has already experienced the wave from the BA.4 and BA.5 variants, which turned out to be less deadly. Tulio de Oliveira, the director of the Centre for Epidemic Response and Innovation at Stellenbosch University in South Africa, said the wave may have been less deadly because hospitals were empty and ready to receive patients or because the population already had a strong immunity, whether through vaccines or previous infection, per The Guardian.

RELATED
Children can get omicron variant even if they’ve already had COVID-19

COVID-19 at high levels in 5 Utah counties. Here’s what CDC says you need to do
Symptoms for omicron can appear from two to 14 days after exposure.

The symptoms for BA.4 and BA.5 are mostly mild, including fever, tiredness and a loss of smell, as I previously reported.

Share RecommendKeepReplyMark as Last Read


From: usual_suspects6/24/2022 1:04:33 PM
   of 16226
 
Breast cancer can metastasize more efficiently while asleep: study
ctvnews.ca

Solution: Restart the body

Share RecommendKeepReplyMark as Last Read


From: Pogeu Mahone6/29/2022 11:35:59 AM
   of 16226
 
Elmo Dies Of Myocarditis After Receiving COVID Vaccine



CELEBS · JUN 28, 2022

SESAME STREET - Reports have confirmed that beloved Sesame Street resident Elmo died unexpectedly this morning just a few hours after receiving the COVID vaccine.

"Elmo not feeling so good," Elmo reportedly said just moments before collapsing.

Officials concluded the cause of death to be "unknown" although medical examiners claim he died of massive heart failure due to Myocarditis - a disease almost never observed in 3-year-olds like Elmo.

"It's important to remember that our friend Elmo's death had nothing to do with the COVID vaccine, which is safe and effective," said Big Bird to reporters. "There is growing evidence that Myocarditis is caused by climate change. That's why you need to eat bugs and stop using SUVs, kids!"

Another local resident Oscar the Grouch claimed his neighbors are being used as pawns to make billions for Big Pharma even if it costs innocent lives. "Open your eyes, people!" he said before being shushed by Big Bird and carried away by FBI agents.

Elmo is survived by his two loving parents and his handlers at Pfizer.

Satan held a press conference today responding to the big loss of Roe v. Wade. He's doing his best to keep his chin up.

Subscribe to The Babylon Bee on YouTube

Share RecommendKeepReplyMark as Last Read


From: Pogeu Mahone6/30/2022 8:43:02 AM
   of 16226
 
Eat Real Food for your vitamins and Minerals. Do not take Junk supplements

BA.5
Top NY Doctor: New COVID Wave Is Starting, With the ‘Worst Version' of Omicron

The BA.5 subvariant of the omicron variant of COVID-19 appears to be on the rise in New York City and fueling a possible sixth wave of the pandemic

Published June 28, 2022 • Updated on June 29, 2022 at 10:21 am

A new COVID wave appears to be starting in New York City, fueled by the strongest subvariant of the omicron strain of coronavirus to date, one of the city's top epidemiologists said Tuesday.

The BA.5 subvariant, first seen in South Africa and then Portugal, is considered by some experts to be the "worst version" of omicron seen yet, given its apparent capacity to escape prior immunity and transmit more readily.

Dr. Jay Varma, a Weill Cornell epidemiologist and formerly then-mayor Bill de Blasio's top public health advisor during the pandemic, said infections appear to have stabilized at a high level in the city, rather than dropping.

"The decline of reported #COVID19 cases in NYC has stopped. Reported cases are at a high plateau, which means actual transmission is very high when you account for the >20x under-counting. This is likely the beginning of a BA.5 wave," Varma tweeted.


Transmission rates in the city hit two-month lows last week, but have started to tick up since then. The health department's own testing says BA.5 accounts for 17% of infections, but that data is almost two weeks old now. Nationally, CDC data pegs BA.5 at nearly 37% of cases.

"Experience from other countries means there will be another big increase in NYC #COVID19 infections, including among those who have had #Omicron in past few months," Varma went on to add.

He did note that it's still unclear what a BA.5 wave would mean for hospitalizations and deaths. Citywide COVID hospitalizations and deaths have been falling steadily and are at two-month lows.

The question now, he said, is whether boosters that worked against the BA.1 subvariant six months ago will have any effect against BA.5.

Copyright NBC New York

Share RecommendKeepReplyMark as Last Read


To: Yorikke who wrote (16170)6/30/2022 10:40:44 AM
From: Pogeu Mahone
   of 16226
 
Too much PFAS in your water?


Share RecommendKeepReplyMark as Last Read


From: teevee7/1/2022 11:53:33 PM
1 Recommendation   of 16226
 
amyloidosis report from mortician

brighteon.com

Steve Kirsch confirms embalmer story and provides data on number of occurrences

stevekirsch.substack.com

It appears that vaccines are involved in 50-90% of deaths according to embalmers' accounts of frequency of amyloids found during embalming process. This indicates vaccine deaths are greatly under reported (reported as heart attack, acute liver or kidney failure, SADS, Strokes). Govts are surely aware of embalmers' reports. The only rational conclusion is this is a gov't depopulation program. The 3 jab Omicron vaccine will accelerate rate of deaths as more spike triggers amyloidosis followed by organ and heart failure and death. The only way to stop this is for people to be informed, and refuse more jabs.

when vax spike protein encounters your body's proteins, it can trigger amyloidosis (proteins fold and trigger a cascade, forming long, "rubbery like" threads & strings in capillaries and blood vessels). Each jab makes the problem worse until critical organ or heart failure. Prognosis for humanity is not good. It will take the control group decades if not centuries to recover.

Share RecommendKeepReplyMark as Last Read


From: Pogeu Mahone7/6/2022 12:12:40 PM
   of 16226
 
7% OF AMERICAN ADULTS HAVE GOOD CARDIOMETABOLIC HEALTH
JULY 5TH, 2022

POSTED BY LISA LAPOINT-TUFTS

"We need a complete overhaul of our healthcare system, food system, and built environment, because this is a crisis for everyone, not just one segment of the population," says Meghan O'Hearn. (Credit: Leo Reynolds/Flickr)

TAGS
BLOOD PRESSURE BODY WEIGHT CHOLESTEROL DIABETES HEARTS UNITED STATES

UNIVERSITY
TUFTS UNIVERSITY

Less than 7% of the adult population of the United States has good cardiometabolic health, research finds.

It’s a devastating health crisis requiring urgent action, according to research led by a team from the Friedman School of Nutrition Science and Policy at Tufts University. Their work appears in the Journal of the American College of Cardiology.

Researchers evaluated Americans across five components of health: levels of blood pressure, blood sugar, blood cholesterol, adiposity (overweight and obesity), and presence or absence of cardiovascular disease (heart attack, stroke, etc.). They found that only 6.8% of US adults had optimal levels of all five components as of 2017-2018.

Among these five components, trends between 1999 and 2018 also worsened significantly for adiposity and blood glucose. In 1999, 1 out of 3 adults had optimal levels for adiposity (no overweight or obesity); that number decreased to 1 out of 4 by 2018. Likewise, while 3 out of 5 adults didn’t have diabetes or prediabetes in 1999, fewer than 4 out of 10 adults were free of these conditions in 2018.

“These numbers are striking. It’s deeply problematic that in the United States, one of the wealthiest nations in the world, fewer than 1 in 15 adults have optimal cardiometabolic health,” says Meghan O’Hearn, a doctoral candidate at the Friedman School and the study’s lead author. “We need a complete overhaul of our health care system, food system, and built environment, because this is a crisis for everyone, not just one segment of the population.”

The study looked at a nationally representative sample of about 55,000 people aged 20 years or older from 1999 to 2018 from the 10 most recent cycles of the National Health and Nutrition Examination Survey. The research team focused on optimal, intermediate, and poor levels of cardiometabolic health and its components, rather than just presence or absence of disease. “We need to shift the conversation, because disease is not the only problem,” O’Hearn says. “We don’t just want to be free of disease. We want to achieve optimal health and well-being.”

The researchers also identified large health disparities between people of different sexes, ages, races and ethnicities, and education levels. For example, adults with less education were half as likely to have optimal cardiometabolic health compared with adults with more education, and Mexican Americans had one-third the optimal levels versus non-Hispanic white adults. Additionally, between 1999 and 2018, while the percentage of adults with good cardiometabolic health modestly increased among non-Hispanic white Americans, it went down for Mexican American, other Hispanic, non-Hispanic Black, and adults of other races.

“This is really problematic. Social determinants of health such as food and nutrition security, social and community context, economic stability, and structural racism put individuals of different education levels, races, and ethnicities at an increased risk of health issues,” says Dariush Mozaffarian, dean of the Friedman School and senior author.

The study also assessed “intermediate” levels of health—not optimal but not yet poor—including conditions like pre-diabetes, pre-hypertension, and overweight. “A large portion of the population is at a critical inflection point,” O’Hearn says. “Identifying these individuals and addressing their health conditions and lifestyle early is critical to reducing growing healthcare burdens and health inequities.”

The consequences of the dire state of health among US adults reach beyond personal health. “Its impacts on national health care spending and the financial health of the entire economy are enormous,” O’Hearn says. “And these conditions are largely preventable. We have the public health and clinical interventions and policies to be able to address these problems.

“This is a health crisis we’ve been facing for a while,” O’Hearn says. “Now there’s a growing economic, social, and ethical imperative to give this problem significantly more attention than it has been getting.”

Source: Tufts University



Share RecommendKeepReplyMark as Last ReadRead Replies (1)


From: Hugh Bett7/11/2022 3:48:00 PM
3 Recommendations   of 16226
 
Berry good:

Berry good: Researchers discover lifespan-extending compound in blueberries – NaturalNews.com

Share RecommendKeepReplyMark as Last Read


From: Pogeu Mahone7/12/2022 5:25:21 PM
   of 16226
 
WARNING LETTER

Lianhuaqingwencaps.comMARCS-CMS 608667 — JULY 06, 2020
Share Tweet Linkedin EmailPrint

Product:Drugs

Recipient:Lianhuaqingwencaps.com304 Tarrigart DriveMoore, SC 29369United States

support@lianhuaqingwencaps.com
Issuing Office:Center for Drug Evaluation and Research | CDERUnited States

Federal Trade Commission

WARNING LETTER

Date: July 6, 2020

RE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)

This is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) reviewed your website at the Internet address lianhuaqingwencaps.com on June 15, 2020, and July 1, 2020, respectively. The FDA has observed that your website offers a traditional Chinese medicine (TCM) product for sale in the United States and that this product is intended to mitigate, prevent, treat, diagnose, or cure COVID-19 [1] in people. Based on our review, this product is an unapproved new drug sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Furthermore, this product is a misbranded drug under section 502 of the FD&C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of this product into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d).

There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS. [2] In addition, on March 13, 2020, the President declared a national emergency in response to COVID-19. [3] Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of such unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.

Some examples of the claims on your website that establish the intended use of your product and misleadingly represent it as safe and/or effective for the treatment or prevention of COVID-19 include:

A graphic with the image of your product Lianhua Qingwen Capsules under the header “CAPS AGAINST COVID-19 . . .” [from your website lianhuaqingwencaps.com]“LIANHUA QINGWEN CAPS TREATS MILD FEVER COUGH AND FATIGUE IN C-VIRUS PNEUMONIA . . .” [from your website lianhuaqingwencaps.com]“Lianhua Qingwen 24 capsules . . . has also been identified as having potential antiviral activity against coronaviruses such as SARS-CoV-2.” [from your website lianhuaqingwencaps.com]“Traditional Chinese Medicine Lianhua Qingwen Plays an Important Role in Fighting Against COVID-19. . . It has been listed in the ‘Diagnosis and Treatment Plan for COVID-19 Infection’ (Trial Version 4/5/6/7) of the China Health and Health Commission and recommended drugs in the diagnosis and treatment plans of COVID-19 of the Health and Health Commission of 20 provinces. . .” [from your website lianhuaqingwencaps.com]Research Provides Scientific Evidence for Lianhua Qingwen . . . The antiviral effect of Lianhua Qingwen has been confirmed by a large number of scientific researches. . . Professor Yang Zifeng . . . said ‘[L]ianhua Qingwen capsule (granule) showed significant cytopathic effect of inhibiting COVID-19 virus. It is known for all that the COVID-19 virus is not only a virus, but also causes a series of over-expression of inflammation. Therefore, people have also observed that Lianhua Qingwen capsule (granule) inhibits the over-expression of human common coronavirus (HcV-229E), novel coronavirus (COVID-19) infected cells and induced inflammatory factors such as TNF-a, IL-6, CCL2/MCP-1 and CXCL-10/IP-10. This is consistent with clinical inflammatory factors. ’[sic]This just proves that Lianhua Qingwen has the multi-target effect of inhibiting novel coronavirus and resisting inflammation.” [from your website lianhuaqingwencaps.com]“Lianhua Qingwen is widely used in epidemic prevention and control, helping the global epidemic prevention and control.” [from your website lianhuaqingwencaps.com]“Tags: 19 . . . covid . . . inhibitor” [from your website lianhuagingwencaps.com]You should take immediate action to correct the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&C Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov describing the specific steps you have taken to correct these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Failure to immediately correct the violations cited in this letter may result in legal action, including, without limitation, seizure and injunction.

FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and/or effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&C Act. This list can be found at fda.gov. Once you have taken corrective actions to cease the sale of your unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and such actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken appropriate corrective action.

If you cannot complete corrective action within 48 hours, state the reason for the delay and the time within which you will complete the corrections. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.

If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs are subject to detention and refusal of admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.

Please direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov.

In addition, it is unlawful under the FTC Act, 15 U.S.C. 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the product identified above. Thus, any coronavirus-related prevention or treatment claims regarding such product are not supported by competent and reliable scientific evidence. You must immediately cease making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. Within 48 hours, please send an email to Richard Cleland, Assistant Director of the FTC’s Division of Advertising Practices, via electronic mail at rcleland@ftc.gov describing the specific actions you have taken to address the FTC’s concerns. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at 202-326-3088 .



Sincerely,

/S/

Donald D. Ashley
Director
Office of Compliance
Center for Drug Evaluation and Research
Food and Drug Administration



Sincerely,

/S/

Serena Viswanathan
Acting Associate Director
Division of Advertising Practices
Federal Trade Commission




[1] As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).

[2] Secretary of Health and Human Services Alex M. Azar II, Determination that a Public Health Emergency Exists. Jan. 31, 2020. (Accessible at phe.gov. The declaration was renewed for another 90 days on April 21, 2020. Secretary of Health and Human Services Alex M. Azar II, Renewal of Determination that a Public Health Emergency Exists. April 21, 2020. (Accessible at phe.gov.

[3] President Donald J. Trump, Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19). Mar. 13, 2020. (Accessible at whitehouse.gov.

Content current as of:07/07/2020



Regulated Product(s)Drugs


More Warning Letters

Warning Letters

About Warning and Close-Out Letters



Footer Links
FDA Archive About FDA Accessibility
Visitor Information Website Policies / Privacy No FEAR Act

Share RecommendKeepReplyMark as Last Read
Previous 10 Next 10